Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis

被引:69
作者
Ma, Pan [1 ]
Liu, Jing [1 ]
Qin, Juan [4 ]
Lai, Lulu [2 ]
Heo, Gyu Seong [3 ]
Luehmann, Hannah [3 ]
Sultan, Deborah [3 ]
Bredemeyer, Andrea [1 ]
Bajapa, Geetika [1 ]
Feng, Guoshuai [1 ]
Jimenez, Jesus [1 ]
He, Ruijun [1 ]
Parks, Antanisha [1 ]
Amrute, Junedh [1 ]
Villanueva, Ana [2 ]
Liu, Yongjian [3 ]
Lin, Chieh-Yu [2 ]
Mack, Matthias [5 ]
Amancherla, Kaushik [6 ]
Moslehi, Javid [1 ,4 ]
Lavine, Kory J. [1 ,2 ]
机构
[1] Washington Univ, Sch Med, Cardiovasc Div, Dept Med, 660 S Euclid,Campus POB 8086, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA
[3] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO USA
[4] Univ Calif San Francisco, Div Cardiol, Dept Med, 555 Mission Bay Blvd South,Rm 252G,UCSF POB 3120, San Francisco, CA 94143 USA
[5] Univ Klinikum Regensburg Klin, Dept Internal Med 2, Nephrol, Regensburg, Germany
[6] Vanderbilt Univ, Med Ctr, Dept Medi, Nashville, TN USA
基金
美国国家卫生研究院;
关键词
CXCL9; chemokine; cytotoxic T lymphocyte-associated antigen 4-immunoglobulin; IFN-gamma; macrophages; myocarditis; programmed cell death protein 1; T-cells; ACTIVATION; IPILIMUMAB; MONOCYTES; NIVOLUMAB; SUBSETS; CCR2; AXIS;
D O I
10.1161/CIRCULATIONAHA.122.062551
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Immune checkpoint inhibitors (ICIs), antibodies targeting PD-1 (programmed cell death protein 1)/PD-L1 (programmed death-ligand 1) or CTLA4 (cytotoxic T-lymphocyte-associated protein 4), have revolutionized cancer management but are associated with devastating immune-related adverse events including myocarditis. The main risk factor for ICI myocarditis is the use of combination PD-1 and CTLA4 inhibition. ICI myocarditis is often fulminant and is pathologically characterized by myocardial infiltration of T lymphocytes and macrophages. Although much has been learned about the role of T-cells in ICI myocarditis, little is understood about the identity, transcriptional diversity, and functions of infiltrating macrophages. METHODS: We used an established murine ICI myocarditis model (Ctla4(+/-)Pdcd1(-/-) mice) to explore the cardiac immune landscape using single-cell RNA-sequencing, immunostaining, flow cytometry, in situ RNA hybridization, molecular imaging, and antibody neutralization studies. RESULTS: We observed marked increases in CCR2 (C-C chemokine receptor type 2)(+) monocyte-derived macrophages and CD8(+) T-cells in this model. The macrophage compartment was heterogeneous and displayed marked enrichment in an inflammatory CCR2(+) subpopulation highly expressing Cxcl9 (chemokine [C-X-C motif] ligand 9), Cxcl10 (chemokine [C-X-C motif] ligand 10), Gbp2b (interferon-induced guanylate-binding protein 2b), and Fcgr4 (Fc receptor, IgG, low affinity IV) that originated from CCR2(+) monocytes. It is important that a similar macrophage population expressing CXCL9, CXCL10, and CD16 alpha (human homologue of mouse FcgR4) was expanded in patients with ICI myocarditis. In silico prediction of cell-cell communication suggested interactions between T-cells and Cxcl9(+)Cxcl10(+) macrophages via IFN-gamma (interferon gamma) and CXCR3 (CXC chemokine receptor 3) signaling pathways. Depleting CD8(+) T-cells or macrophages and blockade of IFN-gamma signaling blunted the expansion of Cxcl9(+)Cxcl10(+) macrophages in the heart and attenuated myocarditis, suggesting that this interaction was necessary for disease pathogenesis. CONCLUSIONS: These data demonstrate that ICI myocarditis is associated with the expansion of a specific population of IFN-gamma-induced inflammatory macrophages and suggest the possibility that IFN-gamma blockade may be considered as a treatment option for this devastating condition.
引用
收藏
页码:48 / 66
页数:19
相关论文
共 52 条
[1]  
Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]
[2]   The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart [J].
Altara, Raffaele ;
Mallat, Ziad ;
Booz, George W. ;
Zouein, Fouad A. .
JOURNAL OF IMMUNOLOGY RESEARCH, 2016, 2016
[3]   Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity [J].
Archilla-Ortega, Adria ;
Domuro, Carla ;
Martin-Liberal, Juan ;
Munoz, Purificacion .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
[4]   T cells specific for α-myosin drive immunotherapy-related myocarditis [J].
Axelrod, Margaret L. ;
Meijers, Wouter C. ;
Screever, Elles M. ;
Qin, Juan ;
Carroll, Mary Grace ;
Sun, Xiaopeng ;
Tannous, Elie ;
Zhang, Yueli ;
Sugiura, Ayaka ;
Taylor, Brandie C. ;
Hanna, Ann ;
Zhang, Shaoyi ;
Amancherla, Kaushik ;
Tai, Warren ;
Wright, Jordan J. ;
Wei, Spencer C. ;
Opalenik, Susan R. ;
Toren, Abigail L. ;
Rathmell, Jeffrey C. ;
Ferrell, P. Brent ;
Phillips, Elizabeth J. ;
Mallal, Simon ;
Johnson, Douglas B. ;
Allison, James P. ;
Moslehi, Javid J. ;
Balko, Justin M. .
NATURE, 2022, 611 (7937) :818-+
[5]   Tissue Resident CCR2-and CCR2+Cardiac Macrophages Differentially Orchestrate Monocyte Recruitment and Fate Specification Following Myocardial Injury [J].
Bajpai, Geetika ;
Bredemeyer, Andrea ;
Li, Wenjun ;
Zaitsev, Konstantin ;
Koenig, Andrew L. ;
Lokshina, Inessa ;
Mohan, Jayaram ;
Ivey, Brooke ;
Hsiao, His-Min ;
Weinheimer, Carla ;
Kovacs, Attila ;
Epelman, Slava ;
Artyomov, Maxim ;
Kreisel, Daniel ;
Lavine, Kory J. .
CIRCULATION RESEARCH, 2019, 124 (02) :263-278
[6]   The human heart contains distinct macrophage subsets with divergent origins and functions [J].
Bajpai, Geetika ;
Schneider, Caralin ;
Wong, Nicole ;
Bredemeyer, Andrea ;
Hulsmans, Maarten ;
Nahrendorf, Matthias ;
Epelman, Slava ;
Kreisel, Daniel ;
Liu, Yongjian ;
Itoh, Akinobu ;
Shankar, Thirupura S. ;
Selzman, Craig H. ;
Drakos, Stavros G. ;
Lavine, Kory J. .
NATURE MEDICINE, 2018, 24 (08) :1234-+
[7]   68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis [J].
Boughdad, Sarah ;
Latifyan, Sofiya ;
Fenwick, Craig ;
Bouchaab, Hasna ;
Suffiotti, Madeleine ;
Moslehi, Javid J. ;
Salem, Joe-Elie ;
Schaefer, Niklaus ;
Nicod-Lalonde, Marie ;
Costes, Julien ;
Perreau, Matthieu ;
Michielin, Olivier ;
Peters, Solange ;
Prior, John O. ;
Obeid, Michel .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
[8]   Myeloid cells as effector cells for monoclonal antibody therapy of cancer [J].
Braster, Rens ;
O'Toole, Tom ;
van Egmond, Marjolein .
METHODS, 2014, 65 (01) :28-37
[9]   Targeting of Gr-l+,CCR2+ monocytes in collagen-induced arthritis [J].
Bruehl, Hilke ;
Cihak, Josef ;
Plachy, Jiri ;
Kunz-Schughart, Leoni ;
Niedermeier, Marianne ;
Denzel, Andrea ;
Gomez, Manuel Rodriguez ;
Talke, Yvonne ;
Luckow, Bruno ;
Stangassinger, Manfred ;
Mack, Matthias .
ARTHRITIS AND RHEUMATISM, 2007, 56 (09) :2975-2985
[10]   Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors [J].
de Moel, Emma C. ;
Rozeman, Elisa A. ;
Kapiteijn, Ellen H. ;
Verdegaal, Els M. E. ;
Grummels, Annette ;
Bakker, Jaap A. ;
Huizinga, Tom W. J. ;
Haanen, John B. ;
Toes, Rene E. M. ;
van der Woude, Diane .
CANCER IMMUNOLOGY RESEARCH, 2019, 7 (01) :6-11